Drug Trial Radar · NCT05050942
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
332
Actual
Start
Oct 22, 2021
Primary completion
Nov 2026
Study completion Nov 2028
Sponsor
- Lead sponsor
- Camurus ABIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029Drug
CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection
Octreotide LARDrug
Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection
Lanreotide ATGDrug
Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)Time frame: From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months
Locations
86 sites in 12 countries. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center (MCCC) - Phoenix
Phoenix, Arizona
UCLA Ahmanson Biological Imaging Center
Santa Monica, California
Rocky Mountain Cancer Centers - Denver - Midtown
Denver, Colorado
Mayo Clinic Hospital - Florida
Jacksonville, Florida
University of Kentucky (UK) - Markey Cancer Center
Lexington, Kentucky
East Jefferson General Hospital
Metairie, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Memorial Sloan-Kettering Cancer Center
New York, New York
Texas Oncology - Austin
Austin, Texas
Texas Oncology - Dallas
Dallas, Texas
The University of Texas - MD Anderson Cancer Center
Houston, Texas
Texas Oncology - McAllen
McAllen, Texas
Texas Oncology - San Antonio Northeast
San Antonio, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
GenesisCare - North Shore
Alexandria, Australia
Fiona Stanley Hospital
Murdoch, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hôpital Erasme
Brussels, Belgium
Antwerp University Hospital
Edegem, Belgium
Algemeen Ziekenhuis Maria Middelares
Ghent, Belgium
AZ Nikolaas
Sint-Niklaas, Belgium
London Health Sciences Centre
London, Canada
Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital
Montreal, Canada
Jewish General Hospital
Montreal, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Niagara Health System - St. Catharines General Site
St. Catharines, Canada
Princess Margaret Cancer Centre
Toronto, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
BC Cancer Agency Vancouver Centre
Vancouver, Canada
CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque
Bordeaux, France
CHRU de Tours - Hopital Trousseau
Chambray-lès-Tours, France
Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital General
Dijon, France
Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de Paul
Lille, France
CHU de Lyon - Groupement Hospitalier Edouard Herriot
Lyon, France
CHU de Nantes - Hôtel-Dieu
Nantes, France
Centre Eugène Marquis
Rennes, France
Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
Strasbourg, France
Charite - UB - CVK - Medizinische Klinik
Berlin, Germany
Universitaetsklinikum Erlangen - Hautklinik
Erlangen, Germany
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.